HomeCVAC • NASDAQ
CureVac BV
$3.05
Pre-market:
$3.09
(1.31%)+0.040
Closed: Mar 28, 4:55:57 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$2.94
Day range
$2.91 - $3.08
Year range
$2.76 - $12.36
Market cap
682.97M USD
Avg Volume
756.01K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(EUR)Sep 2023Y/Y change
Revenue
16.48M47.01%
Operating expense
47.08M17.10%
Net income
-48.68M-2.34%
Net profit margin
-295.3430.39%
Earnings per share
-0.2212.00%
EBITDA
-48.96M-5.59%
Effective tax rate
-0.01%
Total assets
Total liabilities
(EUR)Sep 2023Y/Y change
Cash and short-term investments
464.14M-14.18%
Total assets
842.57M-7.46%
Total liabilities
240.30M-15.84%
Total equity
602.26M
Shares outstanding
223.92M
Price to book
1.09
Return on assets
-15.75%
Return on capital
-20.57%
Net change in cash
(EUR)Sep 2023Y/Y change
Net income
-48.68M-2.34%
Cash from operations
-60.58M-68.67%
Cash from investing
-13.42M51.80%
Cash from financing
-1.21M-104.58%
Net change in cash
-73.78M-125.62%
Free cash flow
-55.99M-2.09%
About
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018. At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Founded
2000
Employees
977
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu